Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannabis sativa crude extract is a botanical preparation derived from the leaves of the *Cannabis sativa* plant, typically obtained through ethanol extraction. In preclinical studies, particularly in pancreatic cancer models like Mia-PaCa2, the crude extract has demonstrated potent anti-cancer activity by triggering programmed cell death. Its mechanism of action involves the modulation of the BCL-2 family of proteins and the activation of the intrinsic apoptotic pathway, leading to DNA fragmentation and cell death. Research indicates that the crude extract may be more effective than isolated cannabinoids like cannabidiol (CBD) due to potential synergistic effects between its various phytochemical components.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cannabis sativa crude extract.